SCHEMBL725215

SCHEMBL725215

C=Cc1cccc2c1CC(=O)N2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 2/20 0.44
PDK2 Q15119 1/20 0.44
DRD2 P14416 4/20 0.42
DRD4 P21917 3/20 0.42
DRD3 P35462 3/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
CHRM2 P08172 1/20 0.42
CYP3A4 P08684 1/20 0.42
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
ADRA2B P18089 1/20 0.42
DRD1 P21728 1/20 0.42
DRD5 P21918 1/20 0.42
HTR2A P28223 1/20 0.42
MAPK1 P28482 1/20 0.42
CYP2C19 P33261 1/20 0.42
ADRA1A P35348 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29612197 1.00 AHR (0.44) AHRPDK2DRD2DRD4DRD3
SCHEMBL2235526 0.84 NPC1 (0.46) HTR1AOPRK1
SCHEMBL30609062 0.84 DRD2 (0.46) AHRPDK2DRD2DRD4DRD3
SCHEMBL13930334 0.84 DRD2 (0.46) AHRPDK2DRD2DRD4DRD3
SCHEMBL4041542 0.75 AHR (0.45) AHRPDK2CCNB2CDK1CCNB1
SCHEMBL31364658 0.72 SMYD3 (0.43) AHRPDK2DRD2HTR1AKCNH2
SCHEMBL4790991 0.72 AHR (0.39) AHRPDK2DRD2DRD4DRD3
SCHEMBL836954 0.72 AHR (0.48) AHRPDK2DRD2DRD4DRD3
SCHEMBL3340538 0.72 AHR (0.48) AHRPDK2DRD2DRD4DRD3
SCHEMBL12326143 0.72 AHR (0.48) AHRPDK2DRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117567351-A Preparation method of 4- (2-bromoethyl) -1, 3-dihydro-2H-indol-2-one 常州锐博生物科技有限公司 2024-02-20 CN disclosed
WO-2023201012-A1 IKZF2 DEGRADERS AND USES THEREOF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-10-19 WO disclosed
CN-112745256-B Preparation method of 4- (2-bromoethyl) -1, 3-dihydro-2H-indol-2-one 常州锐博生物科技有限公司 2022-03-11 CN disclosed
CN-112745256-A Preparation method of 4- (2-bromoethyl) -1, 3-dihydro-2H-indol-2-one 常州锐博生物科技有限公司 2021-05-04 CN disclosed
CN-105385011-B A kind of TPV compositions and automobile collision preventing billot 嘉兴市博尔塑胶有限公司 2018-07-31 CN disclosed
CN-105385011-A TPV composition and automobile anti-collision strip Jiaxing boer plastic co ltd 2016-03-09 CN disclosed
US-9238025-B2 Transdermal preparation comprising a ropinirole derivative HISAMITSU PHARMACEUTICAL CO., INC. (JP) 2016-01-19 US disclosed
US-9238025-B2 Transdermal preparation comprising a ropinirole derivative HISAMITSU PHARMACEUTICAL CO., INC. (JP) 2016-01-19 US disclosed
US-9238025-B2 Transdermal preparation comprising a ropinirole derivative HISAMITSU PHARMACEUTICAL CO., INC. (JP) 2016-01-19 US disclosed
EP-2438917-B1 TRANSDERMAL PREPARATION HISAMITSU PHARMACEUTICAL CO (JP) 2014-09-03 EP disclosed
US-20120052113-A1 TRANSDERMAL PREPARATION HISAMITSU PHARMACEUTICAL CO., INC. (JP) 2012-03-01 US disclosed
US-20120052113-A1 TRANSDERMAL PREPARATION HISAMITSU PHARMACEUTICAL CO., INC. (JP) 2012-03-01 US disclosed
US-20120052113-A1 TRANSDERMAL PREPARATION HISAMITSU PHARMACEUTICAL CO., INC. (JP) 2012-03-01 US disclosed
US-7378439-B2 Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride USV, LTD. (IN) 2008-05-27 US disclosed
US-7378439-B2 Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride USV, LTD. (IN) 2008-05-27 US disclosed
EP-0300614-B1 PROCESS FOR THE PREPARATION OF SUBSTITUTED INDOLINONE DERIVATIVES SMITH KLINE FRENCH LAB (GB) 1993-08-25 EP disclosed
CN-1019296-B IMPROVED PROCESS FOR SUBSTITUTED INDOLINONE DERIVATIVES SMITH KLINE FRENCH LAB (GB) 1992-12-02 CN disclosed
US-4997954-A Process for preparing substituted isoindolinone derivatives SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1991-03-05 US disclosed
EP-0300614-A1 Process for the preparation of substituted indolinone derivatives SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1989-01-25 EP disclosed
CN-1030076-A The improved preparation of the indolinone derivative that replaces SMITH KLINE FRENCH LAB (GB) 1989-01-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120052113-A1 TRANSDERMAL PREPARATION HTR3D, HTR5A, HTR1E AHR 1888/4885PDK2 1998/4885DRD2 959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.